Document is current
Any future updates will be listed below
-
Authors
Lintzeris, Nicholas
Arnold, Jonathon C
McGregor, Iain S
Mills, Llewellyn
- License Information
-
More Information
Article History
Received: 20 July 2025
Accepted: 21 September 2025
First Online: 27 October 2025
Declarations
:
: Prof Lintzeris reports grants from the Australian National Health and MedicalResearch Council (NHMRC) during the conduct of the study; and researchgrants from Camurus and Indivior for unrelated work. Prof McGregor reportsgrants from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeuticsduring the conduct of the study for projects unrelated to the submittedwork; Dr McGregor has patents to WO2018107216A1, WO2017004674A1,and WO2011038451A1 issued and licensed, and patents to AU2017904438,AU2017904072, and AU2018901971 pending. Prof Arnold reports researchgrants from the NHMRC and from Lambert Initiative for Cannabinoid Therapeuticsat the time of the conduct of this research. Prof Arnold has served asan expert witness in various medicolegal cases involving cannabis and hasreceived consulting fees from the World Health Organization (WHO), MedicalCannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiaryof Glaxo Smith-Kline). He is an inventor on patents WO2019227167 andWO2019071302 issued, which relate to cannabinoid therapeutics. No otherauthors report conflicts of interest.
